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Is there a common mechanism for the progression of different degree of tubulointerstitial fibrosis was more closely cor-
types of renal diseases other than proteinuria? Towards the related with the reduction in glomerular filtration rate
unifying theme of chronic hypoxia. The question of why chronic (GFR) than was glomerular pathology, suggesting thatrenal diseases progress is a topic only recently investigated.
glomerular injury was not the major determinant of dis-Putative causes such as proteinuria do not account for all as-
ease progression [2, 3]. There followed a period wherepects of progressive renal disease. An alternative mechanism,
chronic hypoxia, is proposed that might better explain certain the process of nephron hypertrophy was regarded as
elements of progressive renal disease, but elements of the hy- being relevant to glomerular fibrosis and loss of function
pothesis remain subject to further study.
[4]. However, cause-and-effect relationships have never
been established.
Within recent memory, enthusiasms and firmly held
beliefs have come and gone with regard to the question PROTEINURIA AS THE CAUSE OF
of why most chronic renal diseases progress. The need TUBULOINTERSTITIAL SCARRING:
for embracing this area as being of prime importance to UNANSWERED QUESTIONS
nephrologists is largely by default, since, if we cannot Attention subsequently has been directed to the tubu-
prevent disease (because we do not know what causes lointerstitium; in this context, we are now in the throes
it), the next best option is to limit it as far as possible. of a new phase of enthusiasm pointing to proteinuria as
Interestingly, disease progression in nephrology was a the supposed culprit in renal scarring. The idea is that
virtually untouched area until about 15 years ago when protein, which leaks through the diseased glomerulus,
it surfaced in a big way. The discovery by Brenner and injures the tubular cells and thereby involves the intersti-
colleagues that alterations in glomerular hemodynamics tial compartment through the mediation of cytokines
could account for disease progression in the rat, precipi- and infiltrating cells [5]. This idea is supported by a
tated a flood of studies in animals and in man. It emerged number of in vitro studies describing the adverse auto-
that a concept that could be understood by all and which crine and paracrine effects of exposing tubular cells to
could be pursued in simple experiments would lead to
high concentrations of protein [6, 7]. It is worth pointing
a search not only for mechanisms, but for therapies rele-
out, however, that the majority of these in vitro studiesvant to the purported mechanism. At a relatively early
employ high concentrations of bovine serum albumin,stage, however, we pointed out that rats are not humans
but diseases in man in which there is a high filteredand that bets needed to be hedged with regard to the
albumin load—such as occurs in minimal change dis-applicability of glomerular adaptations in rodents to dis-
ease—do not progress, suggesting that albumin per se isease progression in man [1]. One reason for this was the
unlikely to be a pathological agent. The corollary tofact that in other species, such as dogs and rabbits, renal
the proteinuria hypothesis is that anything that reducesdiseases do not mimic the disease in rats. Another reason
proteinuria should abrogate the scarring process. Usedrelated to the interesting observation that in renal biopsy
as strong supporting evidence for this argument is thespecimens from patients with a variety of diseases, the
observation in both diabetic and nondiabetic renal dis-
ease that angiotensin-converting enzyme (ACE) inhibi-
tors, which reduce proteinuria more than do other anti-Key words: progressive renal disease, proteinuria, hypoxia, fibrosis,
tubulointerstitium hypertensives, also slow disease progression more
effectively. Thus, the association between the two is be-Ó 2000 by the International Society of Nephrology
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ing touted as a causal relationship—if the proteinuria pertension with microalbuminuria (30–300 ng/day). We
were able to identify only 3 studies of at least 12 monthscan be limited the damage will be limited. Is this argu-
ment fully supported by current information? duration in which the total number of patients studied
was small (Table 1) [9–11]. A meta-analysis of theseAt this point, it worth considering what criteria should
apply if the hypothesis that proteinuria causes progres- limited studies shows no significant difference between
ACE inhibitors and other antihypertensives in terms ofsive renal scarring is broadly applicable. The following
points are relevant: (1) Non-proteinuric (or minimally an effect on GFR (end point compared to baseline) al-
though ACE inhibitors clearly reduce proteinuria (albu-proteinuric) renal diseases should not be progressive; (2)
whenever there is heavy proteinuria, there should be an minuria) to a greater extent than other antihypertensive
agents. It is evident that the duration of the studies ofincreased tendency for loss of renal function to ensue;
(3) reduction in proteinuria, by whatever means, should such patients, in which the rate of progression of renal
disease is very slow, requires an extended follow-up pe-correlate with slowing of disease progression; and (4) to
establish with certainty that a “renoprotective” agent riod to assess whether ACE inhibitors have any advan-
tage in the setting of minimal proteinuria, such studiesexerts its effect uniquely by reducing the degree of pro-
teinuria, such an agent should be shown to have no other are currently lacking in essential hypertension. Hope-
fully, the final analysis of the study by Jafar et al, alludedrenoprotective effects. Of these points, only the third
point appears to be emerging as fact. Studies in protein- to above, will throw further light on this issue.
uric, nondiabetic nephropathy, comparing the ACE in-
hibitor ramipril with other antihypertensive agents that
THE CHRONIC HYPOXIA HYPOTHESIS
achieve a comparable level of blood pressure control,
Could there be an alternative mechanism of progres-have shown that the ACE inhibitor not only reduces
sion which is common to many forms of primary andproteinuria to a greater extent than do other antihyper-
secondary glomerular disease, and could ACE inhibitorstensives, but that it also slows the progression of renal
work via such a mechanism? We have proposed a mecha-disease while reducing the level of proteinuria [8].
nism that we refer to as the “chronic hypoxia hypothesis”What about common renal diseases that do not fit into
[12]. This hypothesis states that chronic oxygen depriva-this mold and that do not support points 1 and 2 above?
tion to the tubulointerstitial compartment is the underly-First, there is the example of hypertensive nephrosclero-
ing reason for the scarring process and that the basissis, a common cause of end-stage renal disease (particu-
for this is compromise of the postglomerular capillarylarly in the Afro-Caribbean population in the USA) in
circulation.which proteinuria is not a prominent feature. Conversely,
The argument runs as follows: In most glomerularin minimal change disease, a heavy, often-relapsing pro-
diseases, regardless of their cause, there is heterogeneousteinuric state in children, there does not appear to be
involvement of the glomeruli such that some glomeruliconvincing evidence that renal scarring occurs.
are very inflamed with substantial compromise of glo-An important issue is whether ACE inhibitors are
merular capillary patency while other glomeruli escaperenoprotective exclusively via their antihypertensive and
injury, at least initially, and adapt by increasing the fil-antiproteinuric actions (see point 4 above). Recent infor-
tration rates by vasodilating the afferent and efferentmation suggests that these agents may act by mechanisms
arterioles so as to improve glomerular plasma flow. Twoin addition to their blood pressure lowering and antipro-
capillary “circulations” (actually a range) coexist beyondteinuric effects (abstract; Jafar et al, J Am Soc Nephrol
the glomeruli. In one of these, due to the very low flow10:77A, 1999). Based on a statistical analysis of the inter-
through inflamed glomeruli, blood flow and oxygen de-action between urinary protein excretion and ACE in-
livery into the interstitial capillary network is substan-hibitors, the treatment effect of ACE inhibitors appears
tially reduced. In these regions, which show a patchyto be significantly beneficial above a urinary protein ex-
distribution, the balance between oxygen supply and de-cretion of around 750 mg/day (Jafar TH, personal com-
mand would lead to a reduced local oxygen tension,munication). Thus, even when proteinuria is very limited,
which would be chronic and which would impact on theACE inhibitors appear to be renoprotective. It could be
tubulointerstitial compartment. This “ischemia” couldargued that a minimal degree of proteinuria is enough
well be the initiating cause of renin generation and angio-to cause renal scarring and reducing it below this level
tensin II-dependent hypertension. The second “circula-is sufficient to confer protection. This, however, seems
tion” comprises a high-flow peritubular capillary systemto be a highly unlikely scenario.
emanating from vasodilated glomeruli. In the vasodi-To gain further insight into whether protection by
lated glomeruli which escape initial injury, the luck doesACE inhibitors occurs in the absence of proteinuria, we
not hold out for long. The vasodilated state, which allowssurveyed the literature looking for evidence to show
for their hyperfiltration, also exposes the postglomerularthat ACE inhibitors are more renoprotective than other
antihypertensive regimens in patients with essential hy- capillaries to an elevated pressure (if systemic hyperten-
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Table 1. Studies of essential hypertension with minimal proteinuria
Albuminuria, mg/day GFR, mL/min
Total # Age Duration of
Author [Ref] patients years study months Agent Baseline Endpoint Baseline Endpoint
ACE inhibitors
De Venuto [9] 34 20–60 12 Captopril 6.861.2 5.961.9 8565 9265
Ruilope [10] 40 31–63 12 Quinapril 68616 47614 110610 9366
Bigazzi [12] 40 5465 12 Enalapril 77610 2465 11167 102613
Other antihypertensive agents*
De Venuto [9] Beta-blocker 7.961.4 7.862.7 9468 9268
Ruilope [10] “Standard” 52612 77625 10267 9365
Bigazzi [12] Nicardipine 65612 53621 11569 113611
*Same studies as in A; in each study half the total number of patients were administered ACEI and half other antihypertensives
sion coexists) and to increased blood flow. The impact regulation of collagen-I gene transcription is indepen-
dent of this factor, suggesting that hypoxia activates mul-of hypertension would obviously be greatest on the glo-
merular capillaries where there is only the afferent arteri- tiple regulatory pathways within a single cell type.
Much has been written about the causal role of theole to protect them but the hydrostatic pressure effects
must also be transmitted to the postglomerular circula- cytokine transforming growth factor-b1 (TGF-b1) in the
pathogenesis of fibrosis [23, 24]. This is merely one exam-tion, distal to the efferent arteriole. This is normally a
very low-pressure circulation and in this subcompart- ple of a cytokine that mediates the process of scarring
once it is up-regulated. However, something must ini-ment of the interstitium, high flows and pressures are
likely to have an effect on the endothelium of the intersti- tially stimulate the growth factor and maintain it as an
active participant. The same would apply to other cyto-tial capillaries such that endothelial swelling and func-
tional changes start to infringe on flow and oxygen deliv- kines, chemokines and infiltrating cells. The question is
not whether these play a role in the fibrotic processes—ery. The net result would be progressive hypoxia of the
interstitium. they surely do—but rather, what is it that maintains the
elevated levels? The “causes” of the progressive fibrosisCan hypoxia per se induce a fibrogenic response? Hyp-
oxia is a potent regulator of gene expression altering act through these “mediators” and include proteinuria,
uncontrolled hypertension and chronic hypoxia. Hyp-expression (both negatively and positively) of a broad spec-
trum of molecules including growth factors, hormones, oxia is known to induce a wide variety of growth factors
[13, 14], including many of those implicated in the patho-vasoactive compounds and enzymes involved in interme-
diary metabolism [13–16]. In a series of in vitro studies genesis of progressive renal disease, most notably TGF-b1
and platelet-derived growth factor (PDGF) [13, 23], butwe have shown that hypoxia (1% O2) is a profibrogenic
stimulus for tubular epithelial cells, interstitial fibroblasts the up-regulation of vascular endothelial growth factor
(VEGF) by low oxygen [25] may have important reper-and renal microvascular endothelial cells (Table 2) [17;
Norman et al, manuscript submitted for publication]. In cussions on microvascular endothelial cell function. In-
creased expression of VEGF has been reported in dis-response to a low pO2, there is accumulation of extracel-
lular matrix (ECM) proteins as a result of both increased eased kidneys [26] although the functional repercussions
of the increase has not been established. Persistent andmatrix synthesis and decreased matrix degradation medi-
ated by decreased expression of the matrix-degrading progressive hypoxia within the tubulointerstitium could
induce and maintain increased growth factor expressionenzymes, the matrix metalloproteinases (MMPs) [19, 20],
and increased production of the endogenous inhibitors of in this tissue compartment.
There are many causes of scars in the kidney whichthese enzymes, the tissue inhibitors of metalloproteinases
(TIMPs) [21–23]. The mechanisms by which hypoxia elicits are self-limiting and which may have no tendency to
progress. These could occur, for example, following lo-the changes in ECM metabolism in renal cells appear
to involve both transcriptional and post-transcriptional calized inflammation or reflux. Most chronic renal dis-
eases, however, are associated with progressive scarring.events [17; Norman et al, manuscript submitted for publi-
cation]. Transcriptional regulation of genes associated Histologic analysis of chronically scarred kidneys reveals
that much of the microvasculature is missing from thewith fibrogenesis has been shown to occur via both hyp-
oxia-inducible factor-1 (HIF-1)-dependent [17; Norman fibrotic bands of collagen and ECM [27]. Thus, whatever
caused the scar in the first place, leaves the kidney withet al, manuscript submitted for publication], and HIF-
1-independent mechanisms (abstract; Orphanides et al, regions of hypovascularity. The cells lying around the
edges of such areas would sense relative hypoxia. They,J Am Soc Nephrol 10:578A, 1999). Increased expression
of TIMP-1 requires the activation of HIF-1, whereas up- in turn, would mount a fibrogenic response which would
Fine et al: Mechanisms of progressive renal disease S-25
Table 2. Effects of hypoxia (1% O2, 24–48 hours) on human is that they reduce proteinuria. However, it is possible
renal cells in vitro
that these renoprotective agents act via other, as yet un-
PTE CF identified, mechanisms. We therefore asked whether ACE
Viability (LDH release) $ $ inhibitors could protect the kidney by improving intersti-
GAPDH mRNA expression " " tial oxygen delivery. Theoretically, they should be able to
Proliferation (3H-thymidine incorporation) $ "
do this because they dilate the efferent arterioles, reduceProtein synthesis (3H-phenylalanine incorporation) # ND
SMA expression ND " renal vascular resistance and they should improve micro-
Collagen mRNA: vascular flow in the interstitium. To address this, we re-
Collagen I " "
cently described an in vivo model in which the phosphores-Collagen III ND "
Collagen IV $ ND cence of an injected protoporphyrin is inversely related
Collagen production " " to microvascular pO2 (abstract; Norman et al, J Am SocMMP mRNA:
Nephrol 10:666A, 1999). This phosphorescence can beMMP-1 ND #
MMP-2 $ ND measured noninvasively on the surface of an exposed rat
MMP-9 $ ND kidney. Preliminary findings suggest that an ACE inhibitor
MMP protein:
prevents the slow decline in pO2 within the kidney thatMMP-1 ND "
MMP-2 # $ occurs over a 3-hour period of observation, and that
MMP-9 # $ once such a decline has begun, it can be arrested and pO2TIMP mRNA:
increased by bolus administration of an ACE inhibitor.TIMP-1 $ "
TIMP-2 # $ These findings suggest a new renoprotective mechanism
TIMP-3 ND " of action for ACE inhibitors which hinges on improve-
TIMP-1 protein " "
ment of interstitial capillary pO2. Whether this holds upGrowth factors:
TGF-b1 mRNA ND " for chronic administration remains to be seen.
TGF-b1 protein " "
PDGF " "
VEGF " ND UNPROVEN ELEMENTS OF THE CHRONICET-1 " ND
HYPOXIA HYPOTHESISIntegrin expression " "
Transcription factors Our hypothesis requires that evidence of in vivo hyp-HIF-1a mRNA " "
oxia of the kidney should occur at an early stage of theHIF-1a protein " "
progressive kidney disease (prior to microvascular obliter-Abbreviations and symbols are: ": Increased expression; #: Decreased expres-
sion; $: No change in expression; CF: Cortical interstitial fibroblasts; ET-1: ation) due to decreased peritubular capillary flow in some
Endothelin-1; HIF-1a: Hypoxia-induced factor-1, alpha sub-unit; MMP: Matrix
regions and to the endothelial responses to increasedmetalloproteinase; ND: Not tested; PDGF: Platelet-derived growth factor; PTE:
Proximal tubular epithelial cells; SMA: a-smooth muscle actin; TGF-b1: Trans- pressures and flow in others. Thus, evidence of decreased
forming growth factor-b1; TIMP: Tissue inhibitor of matrix metalloproteinase;
pO2 should be demonstrable prior to histologic evidenceVEGF: Vascular endothelial cell growth factor.
of scarring in models of progressive disease.
It also requires that hypoxia persists throughout the
course of the disease which includes the phase of micro-lead to the obliteration of more capillaries, thereby set-
ting up a vicious cycle. vascular obliteration. The ability to detect this in vivo is
now feasible since, even where there is patchy scarring,We would argue that, provided that there is a critical
level of local vascular obliteration associated with the reduced net perfusion of a volume of renal tissue can
be sensed. It will thus be possible to test the hypothesisearly phase of the disease, the surrounding cells will
respond to the hypoxia by expanding the scar, which, fully and to determine whether initiation of therapy with
ACE inhibitors prior to the onset of the disease can delayfor reasons given above, will progress continuously.
In the kidney, the loss of the microvasculature is partic- its onset by improving renal interstitial oxygenation at
the earliest stage of the disease.ularly interesting in that the vessels that are obliterated
are the outflow tracts of the glomeruli, i.e., the peritubu-
lar capillary network [27]. This explains why glomerular ACKNOWLEDGMENTS
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